Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gee, T.
Right arrow Articles by Wise, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gee, T.
Right arrow Articles by Wise, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 47, 431-434
© 2001 The British Society for Antimicrobial Chemotherapy

Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose

T. Gee, J. M. Andrews, J. P. Ashby, G. Marshall and R. Wise,*

Department of Medical Microbiology, City Hospital NHS Trust, Birmingham B18 7QH, UK

The pharmacokinetics and tissue penetration of gemifloxacin were determined during a 24 h period following oral administration of a single 320 mg dose to each of 10 healthy male volunteers. Concentrations of the drug in plasma, inflammatory blister fluid and urine were determined using a microbial assay. A peak plasma concentration (mean ± S.D.) of 2.33 ± 0.5 mg/L was reached at 1.20 ± 0.4 h. Mean penetration into inflammatory fluid was 61.19 ± 10.4%. A peak concentration of 0.74 ± 0.3 mg/L was reached in the inflammatory fluid at a mean time of 3.40 ± 1.7 h. The mean elimination half-life from serum and inflammatory fluid was 5.94 ± 0.4 and 6.27 ± 2.4 h, respectively. Urinary excretion of the drug at 24 h post-dose was 36.11% of the total given. These results demonstrate that gemifloxacin penetrates into the site of inflammation and reaches sufficient concentrations to inhibit many pathogens.

* Corresponding author. Tel: +44-121-554-3801; Fax: +44-121-551-7763; E-mail: r.wise{at}bham.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
F. Islinger, R. Bouw, M. Stahl, E. Lackner, P. Zeleny, M. Brunner, M. Muller, H. G. Eichler, and C. Joukhadar
Concentrations of Gemifloxacin at the Target Site in Healthy Volunteers after a Single Oral Dose
Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4246 - 4249.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Perez, C. Solans, M. A. Bregante, I. Pinilla, M. A. Garcia, and F. Honrubia
Pharmacokinetics and ocular penetration of grepafloxacin in albino and pigmented rabbits
J. Antimicrob. Chemother., October 1, 2002; 50(4): 541 - 545.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Kutlin, P. M. Roblin, and M. R. Hammerschlag
Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model
J. Antimicrob. Chemother., May 1, 2002; 49(5): 763 - 767.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. Cottagnoud, F. Acosta, M. Cottagnoud, and M. G. Tauber
Gemifloxacin Is Efficacious against Penicillin-Resistant and Quinolone-Resistant Pneumococci in Experimental Meningitis
Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1607 - 1609.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. Yague, J. E. Morris, X.-S. Pan, K. A. Gould, and L. M. Fisher
Cleavable-Complex Formation by Wild-Type and Quinolone-Resistant Streptococcus pneumoniae Type II Topoisomerases Mediated by Gemifloxacin and Other Fluoroquinolones
Antimicrob. Agents Chemother., February 1, 2002; 46(2): 413 - 419.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.